Artificial intelligence is becoming increasingly important in pharmaceutical manufacturing, supporting applications such as visual inspection, line clearance, process monitoring and defect detection. As AI adoption grows, manufacturers need confidence that these systems are not only effective, but also controlled, transparent and suitable for use within a regulated GMP environment.
What Is the EU AI Act?
The EU AI Act introduces a common regulatory framework for the development and use of artificial intelligence across the European Union. It follows a risk-based framework with obligations determined by the system’s intended purpose, how it is used and whether it falls within one of the classifications specifically defined in the Act.
For pharmaceutical manufacturers, this makes the intended use of an AI inspection system particularly important. A system that identifies a potential issue for operator review may have a different operational and quality risk profile from one that automatically makes or triggers a critical product quality decision.
How Does the EU AI Act Apply to Pharmaceutical Inspection?
Not every AI system used in pharmaceutical inspection will automatically be classified as high risk. Classification depends on how the system is designed, its intended purpose and the role it plays within the wider manufacturing or quality process.
However, the principles behind the EU AI Act remain highly relevant. Manufacturers should understand how an AI inspection system has been trained, how its performance has been tested and what controls are in place when the system produces an uncertain or incorrect result.
Importantly, compliance with the EU AI Act does not replace established GMP obligations. Any AI-based system used in a GMP process must still be appropriately specified, qualified, validated and maintained in a controlled state according to its intended use and risk.
Why Transparency and Traceability Matter
From 2 August 2026, several further provisions of the AI Act apply, including its targeted transparency requirements. Pharmaceutical manufacturers should assess each system against the applicable classification criteria.
An AI inspection result should be supported by clear and accessible evidence. Operators and Quality teams should be able to understand what the system flagged, review the relevant image or inspection record and trace any actions taken following the result.
Relevant system activity, model and configuration changes, inspection outcomes and significant user decisions should be recorded in accordance with the system’s intended use, risk assessment and applicable GMP data-integrity requirements. In a GMP environment, this helps ensure that AI inspection remains controlled, documented and auditable rather than becoming an unexplained “black box.”
The Importance of Human Oversight
AI can help pharmaceutical inspection become faster, more consistent and less dependent on subjective judgement. However, people must remain appropriately involved in critical quality decisions.
Operators and Quality teams should be able to review inspection evidence, understand the limitations of the AI system and intervene when necessary. AI should support informed decision-making while ensuring that responsibility and oversight remain with trained personnel.
Building Trust in AI-Enabled Pharmaceutical Inspection
The EU AI Act provides an opportunity for pharmaceutical manufacturers to build greater trust in AI-enabled inspection. By considering intended use, risk, data quality, validation, transparency, traceability and human oversight from the beginning, manufacturers can adopt AI in a way that supports innovation while maintaining the control and confidence expected in regulated pharmaceutical manufacturing.
Preparing for Responsible AI Adoption
At Catalyx, we believe AI should enhance quality decisions, not replace them, delivering intelligent inspection solutions that are explainable, auditable and designed for the realities of regulated GMP manufacturing.
As AI adoption continues to grow across life sciences, taking a transparent, compliant approach will be essential to unlocking its full potential while maintaining trust, quality and regulatory confidence.
To speak with a Catalyx subject matter expert about AI adoption in regulated manufacturing, contact us at info@catalyx.ai.